43 results on '"Amboldi, Nadia"'
Search Results
2. Data from Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury
3. Data from Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
4. Supplementary Materials and Methods, Tables S1-S2, and Figures S1-S6 from Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury
5. Supplementary Materials and Methods from Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
6. Supplementary Data from Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor Efficacy
7. Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disorders
8. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition
9. Fragment-based hit discovery and structure-based optimization of aminotriazoloquinazolines as novel Hsp90 inhibitors
10. Discovery of NMS-E973 as novel, selective and potent inhibitor of heat shock protein 90 (Hsp90)
11. Interaction of the Anthracycline 4'-Iodo-4'-Deoxydoxorubicin with Amyloid Fibrils: Inhibition of Amyloidogenesis
12. Antitumor activity of edotecarin in breast carcinoma models
13. Choline and phosphatidylcholine fluorescent derivatives localization in carcinoma cells studied by laser scanning confocal fluorescence microscopy
14. 4′-Iodo-4′-Deoxydoxorubicin Disrupts the Fibrillar Structure of Transthyretin Amyloid
15. Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury
16. Establishment and genomic characterization of the new chordoma cell line Chor-IN-1
17. Abstract 2082: NMS-E668, a potent and selective RET kinase inhibitor characterized by specificity towards VEGFR2 and high antitumor efficacy against RET-driven models
18. Abstract 5163: Characterization of NMS-E194, a selective and potent PERK inhibitor with efficacy in the KMS-11 multiple myeloma
19. Abstract 3795: Novel and selective MELK kinase inhibitors active in breast cancer cell lines
20. Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
21. Abstract A179: NMS-P113, a novel orally available JAK2 selective inhibitor
22. Abstract 798: NMS-P088, a dual FLT3-KIT inhibitor active also on gatekeeper mutations and devoid of QTc prolongation
23. Abstract 74: Establishment and characterization of the new sacral chordoma cell line Chor-IN-1
24. Optimization of Diarylthiazole B-Raf Inhibitors: Identification of a Compound Endowed with High Oral Antitumor Activity, Mitigated hERG Inhibition, and Low Paradoxical Effect
25. Abstract 4539: NMS-P862, a novel orally available selective small molecule Cdc7 inhibitor with antitumor efficacy in breast cancer
26. Corrigendum to “Discovery of NMS-E973 as novel, selective and potent inhibitor of heat shock protein 90 (Hsp90)” [Bioorg. Med. Chem. 21 (2013) 7047–7063]
27. The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia
28. Abstract 2092: The ALK inhibitor NMS-E628 also potently inhibits ROS1 and induces tumor regression in ROS-driven models .
29. The Polo-Like Kinase 1 (PLK1) Inhibitor NMS-P937 Is Effective in a New Model of Disseminated Primary CD56+ Acute Monoblastic Leukaemia
30. Cell Line Identity Finding by Fingerprinting, an Optimized Resource for Short Tandem Repeat Profile Authentication
31. Abstract 3754: Characterization of NMS-P285, a new highly selective and potent BRAF inhibitor
32. Abstract A232: In vitro and in vivo activity of NMS-E628 against ALK mutations resistant to Xalkori.
33. Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor Efficacy
34. Abstract 2522: Identification and characterization of new highly selective and potent BRAF inhibitors
35. Abstract A213: Potent anticancer activityin vitroandin vivoby NMS‐E973, a novel synthetic inhibitor of HSP90
36. Abstract A243: Characterization of NMS-E628, a small molecule inhibitor of anaplastic lymphoma kinase with antitumor efficacy in ALK-dependent lymphoma and non-small cell lung cancer models
37. Identification of N,1,4,4-Tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a Potent, Orally Available Cyclin Dependent Kinase Inhibitor
38. Optimization of Diarylthiazole B-Raf Inhibitors: Identification of a Compound Endowed with High Oral Antitumor Activity, Mitigated hERG Inhibition, and Low Paradoxical Effect.
39. Antitumor activity of edotecarin in breast carcinoma models
40. Corrigendum to “Design and synthesis of functionalized glycomers as non-peptidic ligands for SH2 binding and as inhibitors of A-431 human epidermoid and HT-29 colon carcinoma cell lines” [Bioorg. Med. Chem. Lett. 10 (2000) 439]†
41. Design and synthesis of functionalized glycomers as non-peptidic ligands for SH2 binding and as inhibitors of A-431 human epidermoid and HT-29 colon carcinoma cell lines
42. Reversal of Multidrug Resistance by New Dihydropyridines with Low Calcium Antagonist Activity
43. The Polo-Like Kinase 1 (PLK1) Inhibitor NMS-P937 Is Effective in a New Model of Disseminated Primary CD56+ Acute Monoblastic Leukaemia.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.